# Magnetic Field-Guided Magnetic Nanoparticles as Neurotherapeutics for Neurological Disorders and Glioblastoma

**Authors:** Ming-Chang Chiang, Yu-Ping Yang, Christopher J. B. Nicol

PMC · DOI: 10.3390/life16020293 · 2026-02-09

## TL;DR

This review explores how magnetic fields and magnetic nanoparticles can be used to treat neurological disorders and brain cancer by improving targeted drug delivery and therapy effectiveness.

## Contribution

The paper introduces exosome–magnetic nanoparticle complexes as a novel approach for targeted neurotherapeutics.

## Key findings

- Magnetic nanoparticles show potential for crossing the blood–brain barrier and delivering therapies to the brain.
- Exosome–magnetic complexes enhance targeting and biocompatibility for neurological treatments.
- Magnetic fields can guide nanoparticles to specific brain regions, improving therapeutic outcomes.

## Abstract

Neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), and stroke, are among the most devastating neurological disorders worldwide. Glioblastoma (GBM) is a rapidly growing cancer that originates in astrocytes in the brain. It invades and damages the nervous system. Current treatment options remain limited, primarily due to poor blood–brain barrier penetration, lack of targeted delivery, and limited efficacy in slowing disease progression or promoting functional recovery. In recent years, magnetic fields (MFs) have emerged as a promising therapeutic approach, with mechanisms of action that include direct neuromodulation and the guidance of magnetically responsive nanocarriers to the lesion. Magnetic nanoparticles (MNPs), owing to their unique magnetic properties, biocompatibility, and responsiveness to external MFs, have emerged as promising therapeutic agents for the treatment of neurological diseases and glioblastoma. Exosome–magnetic complexes combine biological carriers with magnetic responsiveness to enhance targeting and biocompatibility for the treatment of neurological diseases and glioblastoma. This review highlights recent advances in magnetic field- and MNP-based neuroprotective strategies and explores new methods for targeted intervention and translational research using exosome–MNP complexes.

## Linked entities

- **Diseases:** Alzheimer’s disease (MONDO:0004975), Parkinson’s disease (MONDO:0005180), stroke (MONDO:0005098), Glioblastoma (MONDO:0018177)

## Full-text entities

- **Genes:** PLAT (plasminogen activator, tissue type) [NCBI Gene 5327] {aka T-PA, TPA}, APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}, SNCA (synuclein alpha) [NCBI Gene 6622] {aka NACP, PARK1, PARK4, PD1}, MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}, BACE1 (beta-secretase 1) [NCBI Gene 23621] {aka ASP2, BACE, HSPC104}
- **Diseases:** thrombosis (MESH:D013927), brain disorders (MESH:D001927), neurological injuries (MESH:D020196), bradykinesia (MESH:D018476), resting tremor (MESH:D014202), nerve damage (MESH:D000080902), atherosclerosis (MESH:D050197), atrial fibrillation (MESH:D001281), Ischemic Stroke (MESH:D002544), cytotoxicity (MESH:D064420), neuronal injury or degeneration (MESH:D009410), embolism (MESH:D004617), infarct (MESH:D007238), depression (MESH:D003866), dementia (MESH:D003704), Lewy (MESH:D018827), muscle rigidity (MESH:D009127), necrosis (MESH:D009336), disorders of the nervous (MESH:D009422), cognitive decline (MESH:D003072), GBM (MESH:D005909), neurological disability (MESH:D009069), brain tumor (MESH:D001932), motor impairment (MESH:D000068079), deterioration of memory (MESH:D008569), injury to (MESH:D014947), Neurodegenerative diseases (MESH:D019636), headache (MESH:D006261), fatty hyaline degeneration (MESH:D008067), inflammation (MESH:D007249), PD (MESH:D010300), mitochondrial dysfunction (MESH:D028361), AD (MESH:D000544), ischemic (MESH:D002545), Tumor (MESH:D009369), BBB disruption (MESH:C536830), cardioembolism (MESH:D000083262), CNS diseases (MESH:D002493), edema (MESH:D004487), neuroinflammation (MESH:D000090862), MFs (MESH:D007922), neurological diseases (MESH:D020271), stroke (MESH:D020521), Neurological Disorders (MESH:D009461), seizures (MESH:D012640), hyperthermia (MESH:D005334), neurofibrillary tangles (MESH:D055956)
- **Chemicals:** Fe3O4 (-), dextran (MESH:D003911), levodopa (MESH:D007980), silica (MESH:D012822), doxorubicin (MESH:D004317), TMZ (MESH:D000077204), cobalt (MESH:D003035), Lipid (MESH:D008055), MnFe2O4 (MESH:C551151), dopamine (MESH:D004298), manganese (MESH:D008345), calcium (MESH:D002118), ROS (MESH:D017382), ferrites (MESH:C001215), magnetite (MESH:D052203), chitosan (MESH:D048271), nickel (MESH:D009532), PEG (MESH:D011092), CoFe2O4 (MESH:C569492), polymer (MESH:D011108), iron (MESH:D007501), iron oxide (MESH:C000499), glutamate (MESH:D018698)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12942359/full.md

---
Source: https://tomesphere.com/paper/PMC12942359